Newswise — When the Dominantly Inherited Alzheimer’s Network started in 2008, there were questions about whether it could succeed. It did. At eight years old, DIAN has fully enrolled its first therapeutic trial and more trials are in planning stages, and its observational cohort study is producing longitudinal data for a quantitative prediction model of Alzheimer’s disease progression. Underpinning the science is a growing international community of families who support each other with warmth and considerable spunk as they navigate both the disease and their intensive research participation to beat it. In a five-part series, Gabrielle Strobel takes the movement’s measure.

About UsFounded in 1996, Alzforum is a news and information resource website dedicated to helping researchers accelerate discovery and advance development of diagnostics and treatments for Alzheimer’s disease and related disorders.

Our site expands the traditional mode of scientific communication by reporting the latest scientific findings and industry news with insightful analysis that puts breaking news into context. We advance research by developing open-access databases of curated, highly specific scientific content to visualize and facilitate the exploration of complex data. Alzforum is a platform to disseminate the evolving knowledge around basic, translational, and clinical research in the field of AD.

Alzforum is supported by a team with backgrounds in science, journalism, information technology, design, and data science. Together with a distinguished Scientific Advisory Board, and the active participation of a global network of scientists, we strive to produce unbiased content to a rigorous editorial standard.

Alzforum is operated by the Biomedical Research Forum (BRF) LLC. BRF is a wholly owned subsidiary of FMR LLC. FMR LLC and its affiliates invest broadly in many companies, including life sciences and pharmaceutical companies. Alzforum does not endorse any specific product or scientific approach.